Imfinzi

Imfinzi is a medicine used to treat lung cancer. It is for use in adults with: - non-small cell lung cancer (NSCLC) that is locally advanced (meaning it has spread into tissues around the lungs, but not to other parts of the body) and cannot be removed by surgery and is not getting worse after radiation treatment and platinum-based chemotherapy (medicines to treat cancer). Imfinzi is used on its own and only when the cancer produces a protein known as PD-L1; - NSCLC that has metastasised (spread) outside the lungs. Imfinzi is given together with tremelimumab (another cancer medicine) and platinum-based chemotherapy, and is used when the cancer has no mutations (changes) in the so-called EGFR and ALK genes; - small cell lung cancer (SCLC) that has spread within the lungs or to other parts of the body (extensive-stage SCLC) and has not been treated previously. Imfinzi is given together with etoposide and either carboplatin or cisplatin (chemotherapy medicines); - biliary tract cancer (BTC), a cancer of the bile ducts (tubes that carry bile from the liver and gallbladder to the gut). It is used in combination with gemcitabine and cisplatin (other cancer medicines) in patients who have not been treated previously, when the cancer cannot be removed by surgery or has metastasised; - hepatocellular carcinoma (HCC), a type of liver cancer, in patients who have not been treated before and whose disease is advanced or cannot be removed by surgery. Imfinzi can be used on its own or in combination with tremelimumab; - endometrial cancer, a cancer of the lining of the womb, when the cancer is advanced or has come back (recurrent). It is used in combination with carboplatin and paclitaxel (chemotherapy medicines) for initial treatment of the disease. For maintenance treatment, it is used on its own when the cancer is mismatch repair deficient (dMMR, meaning that it lacks certain proteins that correct mistakes when DNA in dividing cells is copied) and in combination with olaparib (another cancer medicine) when the cancer is mismatch repair proficient (pMMR, meaning that the repair proteins are present). Imfinzi contains the active substance durvalumab.